Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene

Moshe Shalev, Brian J. Miles, Timothy C. Thompson, Dov Kadmon, M. Shalev, B. J. Miles, T. C. Thompson, G. Ayala, Edward Brian Butler, E. Aguilar-Cordova, D. Kadmon

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Current therapies for localized prostate cancer include radical prostatectomy, local radiation therapy, and cryoablation and are associated with a high rate of cure and acceptable morbidity. However, for men who have failed primary curative attempts or have metastatic disease, no effective therapy associated with acceptable morbidity exists. "Suicide" gene therapy delivered alone or in combination with other forms of treatment could potentially provide simultaneous efficacy against localized and systemic disease via the generation of cytotoxic activity and/or systemic immunity to the cancer. In this article we discuss our preclinical and clinical experience with a herpes-simplex-virus thymidine kinase/ganciclovir gene-therapy protocol for prostate cancer.

Original languageEnglish (US)
Pages (from-to)125-129
Number of pages5
JournalWorld Journal of Urology
Volume18
Issue number2
DOIs
StatePublished - 2000

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene'. Together they form a unique fingerprint.

Cite this